마우스 결핵 모델에서 Isoniazid를 제외한 표준치료의 예비 연구 = Standard Chemotherapy with Excluding Isoniazid in a Murine Model of Tuberculosis

국문 초록 (Abstract)

연구배경: Isoniazid (INH, H)는 4제 표준 항결핵치료의 근간이 되는 중요한 약제이지만 INH를 제외하여도 치료효과에 차이가 없다는 일부 보고들이 있다. 본 연구는 초기 결핵 생쥐 모델을 이용하여 항결핵 표준병합치료에서 INH의 유용성을 평가하였다. 방법: 140마리의 C57BL/6 생쥐를 Glas-Col 장비를 이용하여 약 100개의 H37Rv가 호흡기로 감염되도록 하였다. 감염 4주 후부터 다양한 약제의 조합으로 4~8주간 치료를 시행한 후 감염 후 28주까지 주기적으로 각각 4마리에서 폐와 비장을 적출하여 결핵균 수를 측정하였다. 1군은 약물치료를 시행하지 않은 대조군이었으며, 2군은 INH, rifampicin (RMP, R), ethambutol (EMB, E), pyrazinamide(PZA, Z)로 4주 치료하였고(4HREZ), 3군은 1HREZ/3REZ, 4군은 4REZ, 5군은 4HREZ/4HRE, 6군은 1HREZ/3REZ/4RE, 7군은 4REZ/4RE이었다. 결과: 4주 치료한 군(2~4군)은 치료종료 시점에 폐에서 균이 배양되지 않았으나 치료 종료 12주, 20주 시점에서 다시 균이 검출되었다. 8주 치료한 군(5~7군)은 모두 치료시작 1주까지는 균수가 증가하였다가 2주 후부터 감소하여 치료시작 4주 시점에는 모두 균이 배양되지 않았다. 이후 8주간의 치료를 종료하고 종료 후 16주간 경과 관찰할 때까지(감염 후 28주) 모두에서 균이 배양되지 않았다. 비장에서는 감염 4주 후부터 균이 배양되었다. INH를 전혀 사용하지 않은 7군에서는 치료시작 4주 시점부터 균이 배양되지 않고 이후 감염 28주 시점까지 지속적으로 균이 배양되지 않았다. 반면에 INH를 지속적으로 사용하거나 일시적으로 사용한 5, 6군에서는 치료시작 4주 이후 시점에도 간헐적으로 균이 배양되었다. 결론: 초기 결핵 생쥐 모델에서 INH의 제외는 표준요법의 치료효과에 영향을 미치지 않았다. 향후 만성 결핵생쥐 모델을 이용한 추후 연구가 필요하다.

다국어 초록 (Multilingual Abstract)

Background: Isoniazid (INH, H) is a key drug of the standard first-line regimen for the treatment of tuberculosis (TB), yet some reports have suggested that treatment efficacy was maintained even though INH was omitted from the treatment regimen. Methods: One hundred forty C57BL/6 mice were infected with the H37Rv strain of M. tuberculosis with using a Glas-Col aerosol generation device, and this resulted in depositing about 100 bacilli in the lung. Four weeks after infection, anti-TB treatment was initiated with varying regimens for 4-8 weeks; Group 1: no treatment (control), Group 2 (4HREZ): 4 weeks of INH, rifampicin (R), pyrazinamide (Z) and ethambutol (E), Group 3: 1HREZ/3REZ, Group 4: 4REZ, Group 5: 4HREZ/4HRE, Group 6: 1HREZ/3REZ/4RE, and Group 7: 4REZ/4RE. The lungs and spleens were harvested at several time points until 28 weeks after infection, and the colony-forming unit (CFU) counts were determined. Results: The CFU counts increased steadily after infection in the control group. In the 4-week treatment groups (Group 2-4), even though the culture was negative at treatment completion, the bacilli grew again at the 12-week and 20-week time points after completion of treatment. In the 8-week treatment groups (Groups 5-7), the bacilli did not grow in the lung at 4 weeks after treatment initiation and thereafter. In the spleens of Group 7 in which INH was omitted from the treatment regimen, the culture was negative at 4-weeks after treatment initiation and thereafter. However, in Groups 5 and 6 in which INH was taken continuously or intermittently, the bacilli grew in the spleen at some time points after completion of treatment. Conclusion: TThe exclusion of INH from the standard first-line regimen did not affect the treatment outcome in a murine model of TB in the early stage of disease. Further studies using a murine model of chronic TB are necessary to clarify the role of INH in the standard first-line regimen for treating TB.

참고문헌 (Reference)

1 Rosenthal IM, "Weekly moxifloxacin and rifapentine s more active than the denver regimen in murine uberculosis" 172 : 1457-1462, 2005

2 Centers for Disease Control and Prevention, "Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection" 51 : 998-999, 2002

3 Roberts AD, "Murine model of tuberculosis. In Methods in microbiology" Elsevier Sciences 433-, 2002

4 Nuermberger EL, "Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis" 169 : 421-426, 2004

5 Mitchison DA, "Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis" 133 : 423-430, 1986

6 Centers for Disease Control and Prevention, "Fatal and severe hepatitis associated with rifampin and pyrazinamide or the treatment of latent tuberculosis infection--New York and Georgia, 2000" 50 : 289-291, 2000

7 Lecoeur HF, "Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide" 140 : 1189-1193, 1989

8 Nuermberger E, "Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis" 50 : 2621-2625, 200

9 American Thoracic Society, "Centers for Disease Control and Prevention, Infectious Diseases Society of America. Treatment of tuberculosis" 52 : 1-77, 2003

10 Jindani A, "Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days" 167 : 1348-1354, 2003

11 Bai GH, "Anti-tuberculosis drug resistance in Korea" 16 : 101-107, 2005

12 Grosset J, "Antagonism between isoniazid and the combination pyrazinamiderifampin against tuberculosis infection in mice" 36 : 548-551, 1992

13 Centers for Disease Control and Prevention, "American Thoracic Society. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection-United States, 2003" 52 : 735-739, 2003